Tumor-associated antigens presented by dendritic cells to T-cell receptors

Tumor-associated antigens (TAAs) presented by dendritic cells (DCs) to T-cell receptors (TCRs) constitute the fundamental mechanism of cellular immunity against cancer. Dendritic cells, the most potent professional antigen-presenting cells, capture TAAs from the tumor environment, process them into immunogenic peptides, and display them on Major Histocompatibility Complex (MHC) molecules (Banchereau & Steinman, 1998). This presentation allows for the specific recognition of the MHC-peptide complex by TCRs on naive or memory T cells, providing the necessary signals for T-cell expansion and differentiation into effector cytotoxic T lymphocytes (Mellman & Steinman, 2001). Therapeutic strategies such as dendritic cell vaccines (e.g., Sipuleucel-T) exploit this pathway by priming a patient's immune system ex vivo or in vivo to recognize specific tumor markers (Kantoff et al., 2010). This interaction is a primary target for enhancing anti-tumor immunity and overcoming the immunosuppressive barriers established by malignancies. However, challenges include the identification of truly tumor-specific antigens to avoid autoimmune damage to healthy tissues and the requirement for specific HLA matching in many therapeutic contexts.

Other names

Dendritic cell-presented tumor antigensMHC-peptide-TCR complexAntigen-presenting cell-mediated T-cell activationDC-presented tumor-associated antigens

Dendritic cell-mediated antigen presentation and T-cell activation